Genomic Health

New Cologuard® Modeling Data Show Patient Navigation Matters When Reaching Underserved Populations for Colorectal Cancer (CRC) Screening

Retrieved on: 
月曜日, 10月 25, 2021
The New England Journal of Medicine, Adenoma, Genomic Health, Colorectal cancer, Blood, Cancer, Exact Sciences (company), JAMA, Security (finance), U.S. Securities and Exchange Commission, Patient, FDA, American Cancer Society Cancer Action Network, Risk, Colonoscopy, Annual report, Medicare, Trial of the century, Exact sciences, Multimedia, Oncotype (Denmark), Inflammatory bowel disease, News, National Comprehensive Cancer Network, American Cancer Society, DNA, Dietary supplement, Pharmaceutical industry

Building on the success of Cologuard and Oncotypetests, Exact Sciences is investing in its product pipeline to support patients throughout their cancer diagnosis and treatment.

Key Points: 
  • Building on the success of Cologuard and Oncotypetests, Exact Sciences is investing in its product pipeline to support patients throughout their cancer diagnosis and treatment.
  • Exact Sciences and Cologuard are trademarks or registered trademarks of Exact Sciences Corporation.
  • Cologuard is included in the American Cancer Society's (2018) colorectal cancer screening guidelines and the recommendations of the U.S. Preventive Services Task Force (2016, 2021) and National Comprehensive Cancer Network (2016).
  • Do not use Cologuard if you have had adenomas, have inflammatory bowel disease and certain hereditary syndromes, or have a personal or family history of colorectal cancer.

Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer

Retrieved on: 
木曜日, 10月 7, 2021
Company, Genomic Health, West Pharmaceutical Services explosion, Tumor microenvironment, Intellectual property, Forward-looking statement, OCX, CuriOdyssey, General manager, Master of Pharmacy, COVID-19, Celebrity board director, Physician, Goal, Culture, Drug development, GLOBE, Failure, Diagnosis, Cancer, Growth, U.S. Securities and Exchange Commission, Certification, Maintenance, COO, Accounting, Leadership, Precision, Healthcare Businesswomen's Association, Patient, Neoplasm, Nasdaq, Management, Medicine, Medical imaging

We believe that Giselas years of driving focused, strategic growth will be instrumental in strengthening and expanding our existing capabilities and maximizing new opportunities as a leader in precision oncology diagnostics and monitoring, said Ron Andrews, President and Chief Executive Officer of Oncocyte.

Key Points: 
  • We believe that Giselas years of driving focused, strategic growth will be instrumental in strengthening and expanding our existing capabilities and maximizing new opportunities as a leader in precision oncology diagnostics and monitoring, said Ron Andrews, President and Chief Executive Officer of Oncocyte.
  • Gisela has an incredible track record of servant leadership, and I am confident that her alignment with our Company vision and culture will create sustainable, long-term success for the entire Oncocyte portfolio.
  • Prior to joining Oncocyte, Paulsen was most recently General Manager of Exact Sciences newly acquired Genomic Health, renamed Precision Oncology.
  • Before her time at Roche/Genentech, Paulsen was a General Manager at Health Learning Systems, the founding medical education unit of Ogilvy.

Worldwide Breast Cancer Diagnostics Industry to 2028 - Featuring Koninklijke Philips, Danaher and Hologic Among Others - ResearchAndMarkets.com

Retrieved on: 
水曜日, 9月 15, 2021
Medical Devices, Health, Cancer, Government, PCR, Breast cancer, CAGR, NGS, Segmental analysis (biology), Hologic, Genomic Health, Breast, Mammography, Acquisition, Woman, Medical imaging

The introduction of 3D mammography or digital breast tomosynthesis, which is more accurate than 2D mammography, supports market growth.

Key Points: 
  • The introduction of 3D mammography or digital breast tomosynthesis, which is more accurate than 2D mammography, supports market growth.
  • This advanced technology can detect 40.0% more cancers than 2D mammograms and reduce patient recalls.
  • In January 2021, Hologic Inc. announced that it has agreed to acquire Biotheranostics for approximately US$ 230 million.
  • These tests are mostly used for assessing the efficacy of chemotherapy and targeted therapy in women
    The medical labs and diagnostics centers segment is expected to witness the fastest CAGR over the forecast period due to an increase in platform-based testing such as NGS, and PCR
    Chapter 4 Breast Cancer Diagnostics Market: Type Segment Analysis
    Chapter 5 Breast Cancer Diagnostics Market: Product Segment Analysis
    Chapter 6 Breast Cancer Diagnostics Market: Application Segment Analysis
    Chapter 7 Breast Cancer Diagnostics Market: End-use Segment Analysis
    Chapter 8 Breast Cancer Diagnostics Market: Segment Analysis, By Region, 2017-2028 (USD Million)
    Chapter 9 Breast Cancer Diagnostics Market: Competitive Analysis
    9.1 Recent developments and impact analysis, by key market participants

Exact Sciences and National Surgical Adjuvant Breast and Bowel Project Announce Clinical Validation Study to Detect Minimal Residual Disease in Colorectal Cancer Patients

Retrieved on: 
火曜日, 9月 14, 2021
Oncotype (Denmark), Whole genome sequencing, Patient, CRC, Colon, NCI, Neoadjuvant therapy, Policy, Breast, Solution, Colorectal cancer, Research, Man, Circulating tumor DNA, Neoplasm, U.S. Securities and Exchange Commission, III, Annual report, NASDAQ, Exact Sciences (company), Acquisition, Cancer, Wolmark, Precision medicine, Security (finance), TARDIS, Science, Rollcage Stage II, Blood, National Cancer Institute, DNA, Genomic Health, MRD, Hope, Recurrence, Woman, Technology, Health, Trial of the century, National, Industry, Legislation, Risk, News, Pharmaceutical industry, Medical imaging

MADISON, Wis., Sept. 14, 2021 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, announced today that it has entered into a collaboration agreement with the National Surgical Adjuvant Breast and Bowel Project (NSABP), a cooperative group founded by the National Cancer Institute (NCI). Working together, Exact Sciences and the NSABP plan to conduct a prospective, multicenter validation study with stage II and III colorectal cancer (CRC) patients, demonstrating the ability of Exact Sciences' ctDNA test to detect MRD. The study, called CORRECT-MRD II, is expected to enroll approximately 750 patients at 35 study sites in the U.S. and Canada and is part of Exact Sciences' global initiative to generate clinical validation data for its tumor-informed MRD liquid biopsy test. 

Key Points: 
  • Working together, Exact Sciences and the NSABP plan to conduct a prospective, multicenter validation study with stage II and III colorectal cancer (CRC) patients, demonstrating the ability of Exact Sciences' ctDNA test to detect MRD.
  • "NSABP's expertise in colon research makes them ideal collaborators to conduct this important MRD study in colorectal cancer.
  • Exact Sciences is well-positioned to bring a highly sensitive MRD solution to patients in need.
  • For more information, please visit the company's website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook .

Breast Cancer Diagnostics Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com

Retrieved on: 
月曜日, 9月 13, 2021
Biotechnology, Health, Oncology, Medical Devices, Incidence, Exact sciences, Siemens, Breast cancer, Biopsy, Technology, EGFR, Patient, Growth, BRCA, Southwest Medical Center, Risk, Gene expression, FISH, Disease, IHC, Genomic Health, Breast, Fujifilm, In situ hybridization, Death, COVID-19, GE Healthcare, Abbott Laboratories, Comparative genomic hybridization, Mammography, Hospital, Organization, Association for Molecular Pathology v. Myriad Genetics, Inc., Diagnosis, Acquisition, CGH, Woman, Cancer, Hologic, Medical imaging, Dietary supplement

The "Breast Cancer Diagnostics Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Breast Cancer Diagnostics Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The breast cancer diagnostics market consists of sales of breast cancer diagnostic devices and related services by entities (organizations, sole traders and partnerships) that produce breast cancer diagnostics devices.
  • Therefore, the high-cost diagnosis of breast cancer makes the process a distant option and hinders the growth of the breast cancer diagnostics market.
  • The increasing incidence of breast cancer is expected to drive the growth of the breast cancer diagnostics market.

Talis Biomedical Announces CEO Transition

Retrieved on: 
月曜日, 8月 30, 2021
Company, Therapy, Cancer, Growth, Genomics, U.S. Securities and Exchange Commission, Genomic Health, Acquisition, GLOBE, Exact sciences, Maintenance, Private Securities Litigation Reform Act, Risk, Forward-looking statement, Genentech, Board, Compliance, CEO, Â, Annual report, COVID-19, Infection, Security (finance), Management

The company also announced that Kim Popovits has been appointed as interim CEO and will lead the search efforts to hire the Companys next President and CEO.

Key Points: 
  • The company also announced that Kim Popovits has been appointed as interim CEO and will lead the search efforts to hire the Companys next President and CEO.
  • On behalf of the entire Company and Board of Directors, I would like to thank Brian for his valuable contributions and years of service to Talis.
  • His extraordinary vision and commitment have put us in a strong position, said Felix Baker, Ph.D., chairman of the board of Talis.
  • I look forward to the opportunity to work with the experienced senior leadership team at Talis to scale our operational and commercial capabilities while working with our Board to identify a new CEO to lead the next phase of our growth, said Kim Popovits, interim CEO.

Exact Sciences receives regulatory approval for the Oncotype DX Breast Recurrence Score® Program in Japan

Retrieved on: 
月曜日, 8月 16, 2021
Biology, Breast cancer, Colon, Epic Sciences, Electric Bond and Share Company v. Securities and Exchange Commission, Recurrence, Program, Lymph, Exact Sciences (company), MCRPC, CEO, News, Risk, Genomic Health, Ministry, Collaborative Group on Hormonal Factors in Breast Cancer, Breast cancer classification, Research, Annual report, Security (finance), Patient, Genomics, List of health departments and ministries, Growth, Software, Breast, Neoplasm, Exact sciences, Cancer, DCIS, Nasdaq, Woman, MHLW, Prostate cancer, Dietary supplement, Medical imaging

Breast cancer is the most common cancer in Japanese women, and more than 90,000 new breast cancer cases were diagnosed in Japan in 2020.i The Oncotype DX Breast Recurrence Score Program approved in Japan combines the Oncotype DX Breast Recurrence Score test and software developed for the Japanese market.

Key Points: 
  • Breast cancer is the most common cancer in Japanese women, and more than 90,000 new breast cancer cases were diagnosed in Japan in 2020.i The Oncotype DX Breast Recurrence Score Program approved in Japan combines the Oncotype DX Breast Recurrence Score test and software developed for the Japanese market.
  • "MHLW's approval of Oncotype DX is great news for breast cancer patients in Japan and reflects the powerful evidence backing the Oncotype DX test," said Kevin Conroy, chairman and CEO.
  • In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.
  • NOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Genomic Prostate Score, Oncotype MAP Pan-Cancer Tissue, and Oncotype DX AR-V7 Nucleus Detect are trademarks or registered trademarks of Genomic Health, Inc.

Breast Cancer Diagnostics Global Market Report 2020-2030: COVID-19 Impacts on Procedures, Growth and Changes - ResearchAndMarkets.com

Retrieved on: 
金曜日, 8月 13, 2021
Health, Oncology, Comparative genomic hybridization, Abbott Laboratories, Breast cancer, FISH, Southwest Medical Center, CAGR, EGFR, Genomic Health, Disease, BRCA, IHC, COVID-19, In situ hybridization, Acquisition, Gene expression, Organization, Patient, Growth, Association for Molecular Pathology v. Myriad Genetics, Inc., Breast, Technology, Incidence, Exact sciences, Death, Hospital, Fujifilm, Hologic, Cancer, Diagnosis, Siemens, Woman, GE Healthcare, CGH, Mammography, Biopsy, Pharmaceutical industry, Medical imaging

The breast cancer diagnostics market consists of sales of breast cancer diagnostic devices and related services by entities (organizations, sole traders and partnerships) that produce breast cancer diagnostics devices.

Key Points: 
  • The breast cancer diagnostics market consists of sales of breast cancer diagnostic devices and related services by entities (organizations, sole traders and partnerships) that produce breast cancer diagnostics devices.
  • The high cost of diagnosis of breast cancer is a key factor that hinders the growth of the market for diagnostics of breast cancer.
  • Therefore, the high-cost diagnosis of breast cancer makes the process a distant option and hinders the growth of the breast cancer diagnostics market.
  • By Cancer Type: BRCA Breast Cancer; ER & PR Breast Cancer; HER 2 Breast Cancer; EGFR Mutation Test Breast Cancer; Others

Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021

Retrieved on: 
木曜日, 5月 20, 2021
Branches of biology, Medical genetics, Medical specialties, Exact Sciences, Biology, Genomic Health, Oncotype, Prostate cancer, Breast cancer, Cancer, Medical diagnosis, Kathleen I. Pritchard

"Exact Sciences is changing the way we detect and treat cancer.

Key Points: 
  • "Exact Sciences is changing the way we detect and treat cancer.
  • Building on the success of Cologuard and Oncotype tests, Exact Sciences is investing in its product pipeline to support patients throughout their cancer diagnosis and treatment.
  • For more information, please visit the company\'s website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences , or find Exact Sciences on Facebook.\nNOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Genomic Prostate Score, Oncotype MAP Pan-Cancer Tissue, and Oncotype DX AR-V7 Nucleus Detect are trademarks or registered trademarks of Genomic Health, Inc.
  • Exact Sciences and Cologuard are trademarks or registered trademarks of Exact Sciences Corporation.

Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021

Retrieved on: 
水曜日, 5月 19, 2021
Branches of biology, Medical genetics, Medical specialties, Exact Sciences, Biology, Genomic Health, Oncotype, Prostate cancer, Breast cancer, Cancer, Medical diagnosis, Kathleen I. Pritchard

"Exact Sciences is changing the way we detect and treat cancer.

Key Points: 
  • "Exact Sciences is changing the way we detect and treat cancer.
  • Building on the success of Cologuard and Oncotype tests, Exact Sciences is investing in its product pipeline to support patients throughout their cancer diagnosis and treatment.
  • For more information, please visit the company\'s website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences , or find Exact Sciences on Facebook.\nNOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Genomic Prostate Score, Oncotype MAP Pan-Cancer Tissue, and Oncotype DX AR-V7 Nucleus Detect are trademarks or registered trademarks of Genomic Health, Inc.
  • Exact Sciences and Cologuard are trademarks or registered trademarks of Exact Sciences Corporation.